Niche Service Offering Optivia Biotechnology specializes in transporter screening services and solutions for drug-drug interactions, DMPK, safety, and pharmacology, positioning it as a key partner for biotech and pharma companies seeking specialized transporter assay capabilities.

Recent Acquisition Momentum Following its acquisition by BioIVT in 2018, Optivia is now part of a larger network, potentially providing opportunities for cross-sale of services to an expanded customer base within the CRO and biotech sectors.

Innovative Product Launch The launch of the TransFlex transporter assay system in 2016 demonstrates a commitment to technological advancement, offering new solutions that can appeal to innovation-driven clients looking for cutting-edge assay platforms.

Financial Scale With revenue estimates between 10 to 25 million dollars, Optivia represents a mid-sized biotech CRO with growth potential, making it an attractive target for clients seeking reliable, scalable transporter screening services.

Strategic Location Based in Santa Clara, California, a hub for biotech innovation, Optivia has access to a dense network of pharmaceutical and biotech firms, providing significant sales opportunities through proximity to leading industry clients.